Strive Pharmacy Breaks Ground on New 350,000 Sq. Ft. Arizona Headquarters and Compounding Facility, Strengthening Its National Leadership in Patient-Focused Innovation - registerguard.com
Strive Pharmacy is building a new 350,000 sq. ft. headquarters and compounding facility in Arizona, signaling expansion in the compounding sector.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Compounding outsourcing facilities (503B) and other pharmaceutical manufacturers in the compounding space. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate regulatory deadline.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
A major competitor is expanding its compounding capacity, which may increase market competition and influence industry trends.
Who it affects
Compounding outsourcing facilities (503B) and other pharmaceutical manufacturers in the compounding space.
What you must do
Monitor Strive Pharmacy's expansion and assess potential competitive impacts on your own compounding operations.
Deadline
No immediate regulatory deadline.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal - foxbusiness.com
- The FDA let substandard factories ship these medications to the U.S. - michiganadvance.com
- Tom’s of Maine says it will remedy mold, bacteria problems found by FDA at Sanford plant - mainebiz.biz
- The FTC Challenges Companies’ Allegedly Improper Orange Book Patent Listings - skadden.com
- Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides - drugtopics.com